Experienced in Hepatic Cystic Hamartoma

Dr. Kenneth Sherman

Hepatology
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
41 Years of Experience
Experienced in Hepatic Cystic Hamartoma
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kenneth Sherman is a Hepatologist in Boston, Massachusetts. Dr. Sherman has been practicing medicine for over 41 years and is rated as an Experienced provider by MediFind in the treatment of Hepatic Cystic Hamartoma. His top areas of expertise are Hepatitis, Cirrhosis, Hepatitis C, Hepatitis E, and Liver Transplant.

His clinical research consists of co-authoring 174 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in OH
Hospital Affiliations
Massachusetts General Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO

Locations

THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114

Additional Areas of Focus

Dr. Sherman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

175 Total Publications

HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine: The BEe-HIVe Trial End-of-Study Results.
HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine: The BEe-HIVe Trial End-of-Study Results.
Journal: JAMA
Published: July 02, 2025
Similar Doctors
Fredric Gordon
Advanced in Hepatic Cystic Hamartoma
Dr. Fredric Gordon
Hepatology
Advanced in Hepatic Cystic Hamartoma
Dr. Fredric Gordon
Hepatology

Tufts Medical Center

800 Washington St, 4 South, 
Boston, MA 
 (0.9 miles away)
617-636-4886
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fredric Gordon is a Hepatologist in Boston, Massachusetts. Dr. Gordon is rated as a Distinguished provider by MediFind in the treatment of Hepatic Cystic Hamartoma. His top areas of expertise are Hepatitis, Hepatitis C, Alcoholic Cirrhosis, Liver Transplant, and Endoscopy.

Stephen D. Zucker
Experienced in Hepatic Cystic Hamartoma
Dr. Stephen D. Zucker
Gastroenterology | Hepatology
Experienced in Hepatic Cystic Hamartoma
Dr. Stephen D. Zucker
Gastroenterology | Hepatology

Brigham And Women's Hospital, Division Of Gastroenterology, Hepatology And Endoscopy

45 Francis Street, Asb2-2, 
Boston, MA 
 (2.7 miles away)
617-732-6389
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Stephen Zucker is a member of the faculty of the Division of Gastroenterology, Hepatology and Endoscopy at Brigham and Women’s Hospital, with an academic appointment at Harvard Medical School. Dr. Zucker’s goal is to provide top-quality, compassionate care to his patients employing the most up to date diagnostic and treatment strategies and cutting-edge technology. His responsibilities also include advancing clinical care through involvement in innovative research, as well as training the next generation of physicians by participating in medical student, resident, and fellow educational. Dr. Zucker is rated as a Distinguished provider by MediFind in the treatment of Hepatic Cystic Hamartoma. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Macroamylasemia, Hepatitis, Endoscopy, and Liver Transplant.

Experienced in Hepatic Cystic Hamartoma
Dr. Robert Lowe
Hepatology
Experienced in Hepatic Cystic Hamartoma
Dr. Robert Lowe
Hepatology

Evans Medical Foundation Inc

88 E Newton St, 
Boston, MA 
 (1.8 miles away)
Languages Spoken:
English
See accepted insurances

Robert Lowe is a Hepatologist in Boston, Massachusetts. Dr. Lowe is rated as an Advanced provider by MediFind in the treatment of Hepatic Cystic Hamartoma. His top areas of expertise are Hepatitis, Hepatitis C, Jaundice, Endoscopy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sherman's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile